Twenty eight infants and children (3-63 months) with Kawasaki disease received intravenous immunoglobulins (IVIG) in a multicentric study: Veinoglobulin (Merieux, France) in 24 cases or Sandoglobulln (Sandoz, Switzerland) in 4 cases. The total amount administered was In the range 1-2.5g/Kg and varied from 1 to 5 daily infusions. In 16 cases the patients received 0.4 mg/Kg/day during 5 consecutive days. All of them were given orally acetylsalicylic acid 30 mg/Kg/day during a 2 month period. A dramatic improvement in the patients' general condition was observed, with resolution of fever within 48 hours. Hyperfibrinemia and hyperleucocytosis returned to normal in one week and incresed platelets within 2-3 weeks. An important feature was that follow-up echocardiograms over more than one year have demonstrated no coronary artery abnormalities. Five out of 6 children studied immunologlcally during the acute phase presented with a deficiency of circulating CD8 T cells with an increased CD4/CD8 ratio. High doses of IVIG were followed with an increase of serum IgM, CD8 T cells and a normalisation of CD4/CD8 ratio. High dosage IVIG represents the treatment of choice of Kawasaki syndrome; this activity focuses the deficiency of the immunoregulatory function in Kawasaki syndrome.
Read full abstract